Related Experiment Video
Updated: Jan 11, 2026
Bone Marrow Sampling and Transplants
Pairing JAK with MEK for improved therapeutic efficiency in myeloproliferative disorders
Abstract:
The identification of JAK2 mutations as disease-initiating in myeloproliferative neoplasms (MPNs) has led to new and effective therapies for these diseases. In a study published in this issue of the JCI, Stivala et al. explored the key observation that JAK inhibition successfully suppresses MAPK activation in MPN cell lines and primary MPN cells in vitro, and the finding that it failed to completely and effectively suppress MAPK activation in vivo in two mouse models. The authors went on to show that dual inhibition of JAK and the MAP kinase pathway provided enhanced therapeutic efficacy in the in vivo models of MPN.
Insights
Janus kinase (JAK) inhibition effectively treats myeloproliferative neoplasms (MPNs) in vitro. However, dual JAK and MAP kinase pathway inhibition is needed for enhanced therapeutic efficacy in vivo.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Janus kinase 2 (JAK2) mutations are key drivers of myeloproliferative neoplasms (MPNs).
- JAK inhibitors have shown therapeutic promise in MPNs.
- MAPK pathway activation is observed in MPNs.
Purpose of the Study:
- To investigate the efficacy of JAK inhibition on MAPK activation in MPNs.
- To evaluate the therapeutic potential of combined JAK and MAPK pathway inhibition in MPN models.
Main Methods:
- In vitro studies using MPN cell lines and primary cells.
- In vivo studies utilizing two distinct mouse models of MPN.
- Assessment of MAPK activation following JAK inhibition.
- Evaluation of therapeutic outcomes with single and dual pathway inhibition.
Main Results:
- JAK inhibition suppressed MAPK activation in vitro.
- JAK inhibition failed to completely suppress MAPK activation in vivo.
- Dual inhibition of JAK and MAPK pathways demonstrated enhanced therapeutic efficacy in vivo.
Conclusions:
- Targeting JAK is effective against MPNs, but MAPK pathway crosstalk requires consideration.
- Combined JAK and MAPK pathway inhibition offers a more effective therapeutic strategy for MPNs in vivo.
